Bright Minds Enters Exclusive License Agreement with the University of Illinois
VANCOUVER, BC – April 23, 2021 – Bright Minds Biosciences Inc. (CSE: DRUG) (the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain, is pleased to announce that, pursuant to the exercise of its option under the Option Agreement (as herein defined), it has entered into an exclusive…
